News|Articles|June 1, 2026
Global leader in engagement with healthcare stakeholders
Author(s)Reverba Global
Advertisement
Reverba Global (formerly Health Perspectives Group) is a scientific engagement company that empowers biopharmaceutical companies to connect with patients and healthcare providers to improve health outcomes. Reverba Global’s Patient Experience Engine combines more than 20 years of patient engagement with proprietary scalable technology, compliance expertise and deep scientific knowledge to deliver real-time insights, from discovery through commercialization.
Explore Content Engagement Hub Resources from Reverba Global. Click Below.
- [Intro Video]
Meet Reverba Global Deeper, more impactful engagement with patients and HCPs - [V-Brochure]
The Patient Experience Engine The heart of Reverba Global - [Timeline]
Reverba Global by the numbers 20+ years of scientific patient engagement - [Framework]
reverbaBRIDGE ® Operational platform to enable engagement across functions - [Infographic]
Patient engagement Connecting throughout the product lifecycle - [V-Brochure]
Peer-to-peer mentoring Turning lived experience into measurable impact - [Checklist]
Compliance Experts in privacy and security - [V-Brochure]
Every clinical trial needs navigation ClinOPs GPS™ - [Case Study]
Peer-to-peer mentoring case studies Onboarding, adherence, satisfaction - [Podcast]
Medaffairs evolves The bridge between Clinical and Commerce - [Case Study]
Patient Advisory Councils (PACs) Partnership for ongoing insights - [Fact Sheet]
Global engagement Broad reach requires local relevance
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
2
FDA Approves Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy
3
CVS Restores Coverage of Lilly’s Zepbound, Adds Oral Obesity Drug Foundayo
4
Why Breakthrough Cell and Gene Therapies Still Fail at the Finish Line
5
